Avandia Off The Market; GSK Falls

GlaxoSmithKline plc (NYSE: GSK) shares slipped after UK regulators recommended to take off GSK’s diabetes drug, Avandia, off the UK markets. The regulators expressed concerns over the drug causing an increase in cardiac problems. On September 8, European regulators will be reviewing Avandia and a final decision is anticipated by September 23.

GSK’s shares fell 1.12% to $38.85 at 2:11 pm on Tuesday.

Read more from Benzinga's Company news.